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The cardiovascular system is a major target of thyroid hormone action and the two systems are closely interlinked. It can be greatly
impacted even with subtle alterations in thyroid function. Caution is needed when implementing thyroid hormone replacement in
patients with severe hypothyroidism, especially in the setting of ischemic coronary artery disease. If not properly treated, myxedema
may ensue. Given the high mortality of myxedema coma, supportive care may not always suffice and patients may require more
invasive interventions. We present a challenging case of a patient with overt hypothyroidism with concurrent acute coronary
syndrome which subsequently lead to myxedema coma and cardiogenic shock. A transcaval approach for the delivery of an
Impella 5.0 (Abiomed Inc., Danvers, MA) was utilized in supporting this patient. To our knowledge, this is the first reported
case that describes the use of a mechanical circulatory support in treating myxedema-induced cardiovascular collapse.
1. Introduction
Thyroid function and the cardiovascular (CV) system
have an intricate relationship as patients with untreated
thyroid dysfunction may develop an accelerated onset of
symptomatic CV disease [1]. Modifiable atherosclerotic risk
factors, including hypercholesterolemia, diastolic hyperten-
sion, increased carotid intimal-media thickness, and reduced
endothelial nitric oxide, accompany overt hypothyroidism
and could be reversible with proper TH replacement [2].
Although there is a close relationship between thyroid func-
tion and cardiovascular health, there have been no interven-
tional studies of TH replacement in patients with acute
myocardial infarction that have been published to date,
therefore making a causal relationship between thyroid dys-
function and outcomes difficult to ascertain [1].
We present a challenging case of a patient with overt
hypothyroidism complicated by myxedema with concomi-
tant ischemic heart disease. This case is also remarkable for
the use of a transcaval access for the delivery of an Impella
5.0 (Abiomed Inc., Danvers, MA) in supporting myxedema-
induced cardiovascular collapse, which to our knowledge has
not been previously documented.
2. Case Report
A 41-year-old male, without regular medical care, initially
presented in the outpatient setting with progressive fatigue,
weight gain, shortness of breath, and lower extremity edema
over the past year. At that time, he was diagnosed with
hypothyroidism (TSH 136uIU/mL) and was started on
50μcg PO levothyroxine daily. Two days later, he presented
to the emergency room with chest pain and worsening
shortness of breath. The patient was admitted for further
evaluation which included an ischemic workup for coronary
artery disease.
A diagnostic cardiac catheterization was performed and
the patient was noted to have multivessel obstructive coro-
nary disease with a severely reduced ejection fraction. The
patient subsequently underwent stenting of the left anterior
descending and left circumflex coronary arteries. However,
within 24 hours, the patient developed cardiogenic shock
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and a second percutaneous intervention was emergently
done to address the right coronary artery lesion. Due to
patient’s condition, an intra-aortic balloon pump (IABP)
was utilized and he was transferred to another institution
for escalation of care.
Upon arrival to the second institution, vital signs demon-
strated a blood pressure of 67/31mmHg, a heart rate of
68 bpm, an oral temperature of 35.7°C, a respiratory rate of
14, and an oxygen saturation of 99% on 4 L nasal cannula.
Evaluation of the patient was significant for altered mental
status and signs of systemic hypoperfusion with cold extrem-
ities in the lower extremities. The physical exam also was pos-
itive for bilateral nonpitting edema in all extremities. Further
pertinent positives on the physical exam were notable for
thinned hair to the lateral eyebrows, macroglossia, a waxy,
yellow appearance to his skin, and an absence of hair on
the lower extremities.
Initial laboratory findings included hemoglobin of
7.7 g/dL, platelets of 24K/μL, and a TSH level of 51.09uIU/mL
with free T4 of 0.26ng/dL and free T3<1.0 pg/mL. Thyroid
peroxidase was also noted to be elevated at 209 IU/mL
(normal < 9 IU/mL). An electrocardiogram was obtained
which showed diffuse Q waves (Figure 1). Cardiac moni-
toring was reviewed which demonstrated low-voltage com-
plexes with an intermittent junctional bradycardia. Bedside
echocardiogram revealed severely reduced systolic ejection
fraction of 10% with mild to moderate RV dysfunction.
Patient’s clinical presentation was consistent with myx-
edema coma, and the patient was treated with stress-dose ste-
roids and intravenous levothyroxine. Given the refractory
cardiogenic shock, the IABP was upgraded to a transcaval
Impella 5.0 upon admission. Patient’s clinical condition sub-
sequently improved as his lactate cleared from 5.5mmol/L to
1.1mmol/L; vasopressors were discontinued; Impella wean
commenced over the course of a few days. Unfortunately,
his clinical course was complicated with acute ischemia of
his right lower extremity on day 6 leading to acute renal fail-
ure and sepsis. Ischemia was likely multifactorial with a large
24F venous sheath from the Impella exerting pressure on the
femoral artery also containing 5F arterial line; the patient also
developed an aortic thrombus further impairing perfusion.
Despite emergent revascularization efforts and Impella
removal, the muscles were nonviable. Family was informed
of the need for an above the knee amputation; however, the
family decision was to proceed with comfort care and the
patient died on the 8th day of hospitalization.
3. Discussion
Thyroid function plays a significant role in the health of the
cardiovascular system. Thyroid hormone activates cytopro-
tective mechanisms, stimulates cell growth, and promotes
neoangiogenesis and metabolic adaptation. In the acute
myocardial infarction setting, optimal thyroid function aids
in cardioprotection by reducing myocardial damage and
reversing left ventricular (LV) remodeling [3]. A recent
meta-analysis showed that patients with subclinical hypo-
thyroidism are at higher risk of developing cardiovascular
events, particularly with TSH levels > 10μU/L, and patients
with untreated hypothyroidism are at an increased risk of
bradycardia, systolic and diastolic dysfunction, and increased
peripheral vasoconstriction [3, 4].
Patients with newly diagnosed severe hypothyroidism
and significant cardiovascular risk factors may present a
difficult challenge for the clinician. Great caution is needed
when implementing TH replacement in this subset of
patients, as thyroxine (T4) therapy increases the metabolic
demands of the body which can provoke myocardial ische-
mia. Patients at risk for ischemic heart disease may require
risk stratification for coronary disease. If coronary insuffi-
ciency is apparent, prompt management should be imple-
mented to improve the oxygen supply to the ischemic
myocardium before increasing the myocardial demand
with T4 [5].
It was likely that our patient infarcted prior to initial
presentation to the outside facility and had a preexisting
cardiomyopathy from long-standing, untreated, hypothy-
roidism in addition to underlying ischemic disease. Patient’s
Figure 1: Admission electrocardiogram. Low-voltage junctional bradycardia with anteroseptal and inferior Q waves.
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presentation may be explained by cardiogenic shock alone.
However, patient’s preexisting cardiac insufficiency may
have been further exacerbated after the initiation of T4 ther-
apy along with an additional iodine load from the cardiac
catheterization. This may have triggered a cascade of events
that lead to the development of myxedema coma complicat-
ing the treatment plan.
The incidence of myxedema is roughly 0.22 per million
people per year with mortality rates approaching 30-60%
with treatment [6]. It can develop idiopathically or after
additional stresses to the body such as infection, stroke,
iodine contrast, and myocardial infarction in patients with
preexisting hypothyroidism, as presented in our study [7, 8].
A common source of excess iodine exposure in many patients
results from the use of iodinated contrast media (ICM) for
radiological studies and procedures such as coronary angiog-
raphy, which is well tolerated in most euthyroid individuals
but may lead to thyroid dysfunction in susceptible groups
[9, 10]. The prevalence of thyroid dysfunction after coronary
angiogram contrast exposure is not very well described, and
no specific guidelines exist [9]. Several studies have shown a
clear and definitive association between ICM exposure and
the development of overt hypothyroidism [9, 11, 12]. Case
control studies suggest that ICM exposure at least doubles
the risk of subsequent overt hyperthyroidism and triples the
risk of overt hypothyroidism [9], and Lee et al. noted that
22% of their study population developed an abnormal TSH
within one to four weeks of receiving an elective computed
tomography scan [13].
The main mechanism for iodine contrast-induced
hypothyroidism is known as a failure to escape the Wolff-
Chaikoff effect, first described in 1948 [14]. This effect is
usually transitory and does not typically lead to overt
hypothyroidism. This escape process is mainly due to the
downregulation and reduction in sodium/iodide symporter
(NIS) expression resulting in decreased iodine transport
into the thyroid and subsequent resumption of thyroid hor-
mone synthesis, typically occurring 24 hours after excess
iodine exposure [15–17].
Monitoring of thyroid function should be considered
especially in at-risk patients, as there is a potential for serious
complications including the development of myxedema, as
presented in this case study. Traditional treatment in patients
who develop myxedema includes the use of steroids and TH
replacement therapy. In patients with significant risk factors
for coronary disease, caution should be exercised as giving
high-dose TH replacement will exert an increase in meta-
bolic demand in an otherwise ischemic prone heart. The
use of invasive therapies, such as the use of mechanical cir-
culatory support (MCS), can be considered especially in
patients with concomitant myxedema coma and cardiogenic
shock as they can help support myocardial function by
unloading the left ventricle and reduce diastolic volume.
Multiple trials have demonstrated Impella’s hemodynamic
superiority when compared to IABP in shock and postarrest
patients; its use in patients with concomitant myxedema has
not been studied [18, 19].
Patients who develop myxedema coma and subsequent
cardiovascular collapse are rarely encountered in clinical
practice. Myxedema carries a high mortality alone, and con-
comitant coronary ischemia increases the complexity of the
management for these patients. Timing and magnitude of
hemodynamic support are imperative to consider given the
high mortality and complex nature of these patients. Our
case demonstrates the potential for use of MCS for such
patients with carefully designed protocols to preemptively
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